Wealth Dimensions Group Ltd. Has $666,000 Holdings in Pfizer Inc. (NYSE:PFE)

Wealth Dimensions Group Ltd. increased its position in Pfizer Inc. (NYSE:PFE) by 1.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,791 shares of the biopharmaceutical company’s stock after buying an additional 454 shares during the period. Wealth Dimensions Group Ltd.’s holdings in Pfizer were worth $666,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Olistico Wealth LLC acquired a new position in Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer during the 2nd quarter valued at about $29,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the 4th quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. bought a new stake in Pfizer during the second quarter worth approximately $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE stock opened at $29.27 on Monday. The company has a 50 day moving average price of $29.21 and a 200 day moving average price of $28.13. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.42. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market capitalization of $165.86 billion, a PE ratio of -487.83, a price-to-earnings-growth ratio of 1.04 and a beta of 0.68.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were issued a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.74%. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, September 9th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.